USA / NORD’s Breakthrough Summit: Listening to the Rare Disease Patient Voice
The National Organization for Rare Disorders (NORD) is set to host its annual Rare Diseases and Orphan Products…
USA
USA / 2021 Drug Formulary Exclusions Continue to Reduce Therapy Choice for Consumers
Susan L. Lang outlines how pharma companies can navigate drug formulary exclusions, numbers of which have been rising in recent years, and ensure that newly FDA approved medicines can make…
USA / PhRMA COO: Removing Protections in Medicare Would Harm Seniors
PhRMA’s Lori Reilly warns that, as US policymakers seek to reduce drug prices, they must avoid policies that…
Global / PharmaBoardroom's Top Patient Group Insights 2021
PharmaBoardroom has spoken to leaders from several important global patient advocacy organisations in 2021 who…
In Conversation
Asli Özelli – Executive Director, AmCham Turkey
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Navin Pinto – Attending Physician, Seattle…
Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also…
Brent Ragans – President, Ferring Pharmaceuticals US
Brent Ragans of Ferring Pharmaceuticals US discusses the effects of the COVID-19 pandemic on the company’s operations, their footprint in reproductive health and Crohn’s Disease, virtual product launches and digitalisation,…
Latest Reports
USA Pharma Report 2020
- 2020
The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from stakeholders across regulators, health insurers, pharma and biotech companies, as well as patient and industry associations, to provide an incisive snapshot of the US healthcare industry during one of its most defining periods, look at how far the sector has come and ultimately, how much further still it has to go, in order to achieve its fundamental mission: delivering innovative, quality and life-changing therapies in an accessible and sustainable manner. This exclusive new report is an extensive compilation of insights into the…
Latest Reports
USA Pharma Data Report October 2020
- 2020
HCLS Review USA Data is an extensive compilation of data and infographics from the world’s largest and most important pharmaceutical market. US sales of drugs accounted for 48 percent of the global market for pharmaceuticals in 2019 and pharma market spending is on the rise, with Americans projected to be spending between USD 635 and 655 billion on medicine by 2023. Moreover, the USA is the world’s largest research and development engine, with an estimated USD 60 billion spent every year for this purpose, helping create the innovative treatments of tomorrow. This exclusive new 19-page report contains up-to-date information…
The Future of Biosimilars in the USA
Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the…
USA / PhRMA COO: Removing Protections in Medicare Would Harm Seniors
PhRMA’s Lori Reilly warns that, as US policymakers seek to reduce drug prices, they must avoid policies that…
Switzerland / ISREC’s Susan Gasser: A “Hard-Nosed” Approach to Research Quality & Excellence
After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even…
How the USA’s CREATES Act Restores Competition to the Pharmaceutical…
Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) discusses…
USA / The Value Proposition of Generics & Biosimilars
AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value…
Alzheimer's / Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment…